| answer text |
<p>The 2024 voluntary scheme for branded medicines pricing, access and growth (VPAG)
introduces a new way of controlling the cost of older medicines that is explicitly
pro-innovation and pro-competition. We do not anticipate this resulting in a detrimental
impact on women's health or, given the available mitigations, on the supply of medicines.</p><p>Medicines
for women’s health will be subject to the VPAG in the same way that all other medicines
are. They will be subject to the top up payment percentage only when they have not
seen a sufficient price decline since the active substance lost market exclusivity.</p><p>In
exceptional circumstances, where a product would otherwise be uneconomic to supply,
companies can apply to the Department for a price increase or for an adjustment to
the top up payment percentage that applies.</p>
|
 |
